Home › Research › Drug development
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels
Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC.. Archives of neurology, 2003-07-01
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Background Plasma amyloid beta-protein Abeta42 levels are increased in patients with familial Alzheimer disease (AD) mutations, and high levels reportedly identify individuals at risk to develop AD. Objectives To determine whether there are characteristic changes in plasma Abeta40 and Abeta42 levels in sporadic AD, and to examine the relationship of plasma Abeta measures with clinical, demographic, and genetic variables in a prospectively characterized outpatient clinic population. Patients A total of 371 outpatients with sporadic AD (n = 146), mild cognitive impairment (n = 37), or Parkinson disease (n = 96) and nondemented control cases (n = 92). Methods We collected plasma samples and determined Abeta40 and Abeta42 levels by sandwich enzyme-linked immunosorbent assay with the use of the capture antibody BNT77 (anti-Abeta11-28) and the detector antibodies horseradish peroxidase-linked BA27 (anti-Abeta40) and BC05 (anti-Abeta42). Results Mean Abeta40 and Abeta42 levels increased significantly with age in each diagnostic group. When covaried for age, mean plasma levels of Abeta40 and Abeta42 did not differ significantly among the 4 diagnostic groups. Within the mild cognitive impairment and AD groups, Abeta40 and Abeta42 levels did not correlate with duration of memory impairment or with cognitive test scores. The Abeta measures were not influenced by family history of AD, apolipoprotein E genotype, or current medication use of cholinesterase inhibitors, vitamin E, statins, nonsteroidal anti-inflammatory drugs, or estrogen. Conclusions Plasma Abeta measures increase with age, but, in contrast to reports on familial AD, plasma Abeta measures were neither sensitive nor specific for the clinical diagnosis of mild cognitive impairment or sporadic AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fukumoto, H., Tennis, M., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003). Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Archives of neurology. https://doi.org/10.1001/archneur.60.7.958
Vancouver
Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Archives of neurology. 2003. doi:10.1001/archneur.60.7.958. PMID: 12873852.
BibTeX
@article{fukumoto2003-12873852,
author = {Fukumoto, H. and Tennis, M. and Locascio, J. J. and Hyman, B. T. and Growdon, J. H. and Irizarry, M. C.},
title = {{Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels}},
journal = {Archives of neurology},
year = {2003},
doi = {10.1001/archneur.60.7.958},
pmid = {12873852},
url = {https://doi.org/10.1001/archneur.60.7.958}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Mean Abeta40 and Abeta42 levels increased significantly with age in each diagnostic group.
- When covaried for age, mean plasma levels of Abeta40 and Abeta42 did not differ significantly among the 4 diagnostic groups.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants146
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 26 of the 58 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 2 / 4 | 146 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12873852) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 26 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 26 of the 58 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “p-tau217”
693 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 693 tagged studies.